Investigational drug · Phase 2
OD-07656
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Ulcerative Colitis (UC), UC - Ulcerative Colitis.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "OD-07656"
First trial start
2025
Jun 2, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OD-07656", any sponsor or status.
Conditions studied
As listed on its trial records.
- Ulcerative Colitis (UC)
- UC - Ulcerative Colitis
Approved drugs for the same conditions: Ulcerative colitis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "OD-07656" as an intervention, largest first.
- Phase 1 Study to Investigate OD-07656 in Healthy Adult ParticipantsPivotal-lookingCompleted
Odyssey Therapeutics, Inc.Industry
NCT06206811 · 101 participants · Start Feb 12, 2024 · Primary completion Nov 25, 2024
Drug: OD-07656 · For: Inflammatory Bowel Diseases; Blau Syndrome; Crohn Disease and 2 more
Sites: Melbourne, Australia
Odyssey Therapeutics, Inc.Industry
NCT06850727 · 57 participants (planned) · Start Jun 2, 2025 · Primary completion Apr 2026
Drug: OD-07656; Vedolizumab · For: Ulcerative Colitis (UC); UC - Ulcerative Colitis
Sites: Birtinya, Australia; Box Hill, Australia; Maroochydore, Australia · 32 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Ulcerative Colitis (UC)
- Hemay005Mufemilast, Phosphodiesterase 4 inhibitorsPhase 34 trials
Ganzhou Hemay Pharmaceutical Co., Ltd · Moderate to Severe Ulcerative Colitis, Ulcerative Colitis (UC), COPD (Chronic Obstructive Pulmonary Disease)
- MORF-057zotemtegrast, LY4268989Phase 24 trials
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) · Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis (UC)
- anti-TL1A monoclonal antibodyPhase 22 trials
Biocad · Ulcerative Colitis (UC), Crohn's Disease (CD)
- HSK47388Phase 22 trials
Haisco Pharmaceutical Group Co., Ltd. · Plaque Psoriasis, Ulcerative Colitis (UC)
- INT-210Phase 21 trial
Innatus Therapeutics (Shanghai) Co., Ltd. · Ulcerative Colitis (UC)
- MB-001Phase 21 trial
Mage Biologics · Ulcerative Colitis (UC)
- MGT-006Phase 21 trial
Metagen Therapeutics, Inc. · Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
- MT-201Phase 21 trial
Mirador Therapeutics, Inc. · Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC), Crohn's Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.